| Aaron Medina, DPM | |
|
10800 Magnolia Ave, Riverside, CA 92505-3043 | |
| (951) 315-0989 | |
| Not Available |
| Full Name | Aaron Medina |
|---|---|
| Gender | Male |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 10800 Magnolia Ave, Riverside, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184283616 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | E5951 (California) | Primary |
| Provider Name | Southern California Permanente Medical Group |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1316979834 PECOS PAC ID: 6002729175 Enrollment ID: O20040126000823 |
News Archive
Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second quarter of 2011. Additionally, at the International Gynecologic Cancer Society (IGCS) regional meeting held in New Delhi April 2-3, 2011, Dr. Fred Ueland presented data demonstrating the high sensitivity for ovarian malignancy of OVA1 in combination with ultrasound.
A meningitis epidemic hits West Africa every year, affecting 25 000 to 200 000 people. It has long been known that the timing of this epidemic and its spatial distribution within the "Meningitis Belt", situated between 10° and 15° North, are closely linked to climatic conditions. Involved in the AMMA programme, IRD and University of Paris-VII researcher produced the first quantified description of this relationship using statistical methods.
Genta Incorporated announced today the presentation of combined data on early endpoints from the Company's randomized Phase 3 trials of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced melanoma. The presentation included a "pooled analysis" that assessed combined efficacy results for the endpoints of overall response and progression-free survival from both studies. The data were presented today at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
Protalix BioTherapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease. Taliglucerase alfa is a plant-cell expressed form of glucocerebrosidase (GCD).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aaron Medina, DPM 275 W Macarthur Blvd, Oakland, CA 94611-5641 Ph: () - | Aaron Medina, DPM 10800 Magnolia Ave, Riverside, CA 92505-3043 Ph: (951) 315-0989 |
News Archive
Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second quarter of 2011. Additionally, at the International Gynecologic Cancer Society (IGCS) regional meeting held in New Delhi April 2-3, 2011, Dr. Fred Ueland presented data demonstrating the high sensitivity for ovarian malignancy of OVA1 in combination with ultrasound.
A meningitis epidemic hits West Africa every year, affecting 25 000 to 200 000 people. It has long been known that the timing of this epidemic and its spatial distribution within the "Meningitis Belt", situated between 10° and 15° North, are closely linked to climatic conditions. Involved in the AMMA programme, IRD and University of Paris-VII researcher produced the first quantified description of this relationship using statistical methods.
Genta Incorporated announced today the presentation of combined data on early endpoints from the Company's randomized Phase 3 trials of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced melanoma. The presentation included a "pooled analysis" that assessed combined efficacy results for the endpoints of overall response and progression-free survival from both studies. The data were presented today at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
Protalix BioTherapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease. Taliglucerase alfa is a plant-cell expressed form of glucocerebrosidase (GCD).
› Verified 7 days ago
Leonard L Cano, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Upperline Healthcare California, Pc Podiatrist Medicare: Medicare Enrolled Practice Location: 3600 Central Ave Ste 4, Riverside, CA 92506 Phone: 951-417-4554 | |
Circle City Podiatry Group Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3838 Sherman Dr, Suite 9, Riverside, CA 92503 Phone: 951-352-9228 Fax: 951-352-9357 | |
Stephen R Roberts, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Inland Podiatry Group Inc Podiatrist Medicare: Medicare Enrolled Practice Location: 4049 Almond St, Suite 101, Riverside, CA 92501 Phone: 951-781-3660 Fax: 951-781-3661 | |
Daisy Wu, Dpm, Inc. Podiatrist Medicare: Medicare Enrolled Practice Location: 4646 Brockton Ave, Suite 202, Riverside, CA 92506 Phone: 951-751-9096 Fax: 951-848-9163 |